UPMC Hilman Cancer Center

Pittsburgh, Pennsylvania 15232

1 studies enrolling now · 1 studies all time

What they study most

Refractory Hematologic Malignancy, Refractory Primary Central Nervous System Lymphoma, Relapsed Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma

Studies at this site

• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) — Recruiting now